Zucero is an Australian-based biotechnology company focussed on the development of pixatimod, an immunotherapy for the treatment of cancer. Pixatimod successfully completed safety evaluation in a Phase 1a clinical trial. It is currently under investigation in a Phase 1b study in combination with Opdivo® (immune checkpoint inhibitor) for pancreatic cancer, and new investigations in colon cancer is now being planned.